Bionano Genomics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
BNGO$1.23+6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
BIONANO GENOMICS, INC
Consolidated Statements of Cash Flows
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net loss | $(112,017,000) | $(232,493,000) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization expense | 14,022,000 | 13,708,000 |
| Goodwill impairment | — | 77,280,000 |
| Inventory write-offs | 7,231,000 | — |
| Amortization of financing lease right-of-use asset | 204,000 | 204,000 |
| Accretion of interest on securities | (1,316,000) | (539,000) |
| Net realized loss on investments | 14,000 | 23,000 |
| Non-cash lease expense | (122,000) | 56,000 |
| Gain on lease modification | (73,000) | — |
| Stock-based compensation | 9,736,000 | 15,178,000 |
| Cost of leased equipment sold to customer | 361,000 | 382,000 |
| Change in fair value of contingent consideration | (10,890,000) | (1,462,000) |
| Change in fair value of convertible debentures, convertible notes payable and option liability | (8,118,000) | (575,000) |
| Loss on issuance of convertible debentures | 1,890,000 | 18,827,000 |
| Gain on High Trail extinguishment | (3,965,000) | — |
| Loss on extinguishment of convertible debentures payable | 7,341,000 | — |
| Disposal of internal-use software | 1,293,000 | — |
| Intangible assets and other long-lived assets impairment | 17,850,000 | — |
| Long-lived assets held for sale impairment | 425,000 | — |
| Right-of-use-asset impairment | 1,407,000 | — |
| Disposal of property and equipment | 1,404,000 | — |
| Contingent consideration cash payment in excess of acquisition-date fair value | — | (1,000,000) |
| Changes in operating assets and liabilities | ||
| Accounts receivable | 4,139,000 | (2,296,000) |
| Inventory | (587,000) | (4,150,000) |
| Prepaid expenses and other current assets | 1,583,000 | 1,213,000 |
| Other assets | 4,678,000 | (5,020,000) |
| Accounts payable | (3,420,000) | (1,995,000) |
| Accrued expenses and contract liabilities | (1,992,000) | (2,522,000) |
| Net cash used in operating activities | (68,922,000) | (125,181,000) |
| Investing activities: | ||
| Purigen acquisition, return of purchase consideration from escrow | — | 96,000 |
| Purchases of property and equipment | (103,000) | (1,691,000) |
| Purchase of available for sale securities | (233,021,000) | (111,264,000) |
| Sale and maturities of available for sale securities | 306,963,000 | 137,017,000 |
| Net cash provided by investing activities | 73,839,000 | 24,158,000 |
| Financing activities: | ||
| Principal payments of financing lease liability | (58,000) | (47,000) |
| Proceeds from sale of common stock and warrants | 44,433,000 | 57,697,000 |
| Offering expenses on sale of common stock and warrants | (2,953,000) | (1,444,000) |
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Proceeds from sale of common stock under employee stock purchase plan | 11,000 | 107,000 |
| Proceeds from warrant and option exercises | 4,000 | 23,000 |
| Proceeds from issuance of convertible debentures | 18,000,000 | 80,000,000 |
| Payments on High Trail notes | (61,000,000) | (9,000,000) |
| Payments on convertible debentures | (5,000,000) | — |
| Debt issuance costs on sale of convertible debentures | (1,747,000) | (4,521,000) |
| Payments of retirement fees for redemption of High Trail notes | (5,375,000) | — |
| Contingent consideration milestone payment | — | (9,000,000) |
| Net cash provided by (used in) financing activities | (13,685,000) | 113,815,000 |
| Effect of exchange rates on cash and cash equivalents and restricted cash | (7,000) | 65,000 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | (8,775,000) | 12,857,000 |
| Cash and cash equivalents and restricted cash at beginning of period | 18,348,000 | 5,491,000 |
| Cash and cash equivalents and restricted cash at end of period | $9,573,000 | $18,348,000 |
| Reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets to the total amounts reported on the consolidated statements of cash flows | ||
| Cash and cash equivalents | 9,173,000 | 17,948,000 |
| Restricted cash | 400,000 | 400,000 |
| Total cash and cash equivalents and restricted cash at end of period | $9,573,000 | $18,348,000 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for interest | $10,653,000 | $1,648,000 |
| Cash paid for operating lease liabilities | $2,754,000 | $2,586,000 |
| Supplemental disclosure of non-cash financing and investing activity | ||
| Transfer of instruments and servers from inventory into property and equipment, net | $5,291,000 | $10,979,000 |
| Property and equipment included in accounts payable | $— | $6,000 |
| Debt issuance costs included in accounts payable | $— | $150,000 |
| Conversion of High Trail convertible notes payable into common stock at fair value | $— | $6,542,000 |
| Accrued liability for fees to be paid in common stock | $1,584,000 | $— |
| Non-cash Fill-Up Amount | 472,000 | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.